ClinicalTrials.gg
Active, not recruitingNCT05885555Updated Oct 20, 2026

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

A Phase 2 interventional study of Ianalumab in Primary Immune Thrombocytopenia (ITP), sponsored by Novartis Pharmaceuticals. Active, not recruiting at 24 sites in 13 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Not applicable
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis — 4 open to participants now, 7 under way, 2 of them phase 3. Purpura, Thrombocytopenic, Idiopathic · Novartis.

Enrollment
6th of 12
41 · median 39
Started
2023
with 2 others
Phase 2
7 of 17
2 open now
Registered
10th of 17
by date

Among the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, this one is the 6th largest by enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2023, is one of 7 in phase 2, and was the 10th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

4 of the 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Purpura, Thrombocytopenic, Idiopathic by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the therapeutic efficacy, safety and tolerability of ianalumab in adult patients with primary ITP previously treated with at least one corticosteroid and one TPO-RA.

Read the detailed description

This is a phase 2, open-label, single-arm study to evaluate the efficacy, safety and tolerability of ianalumab in participants with primary ITP (platelet count \<30 G/L at screening) previously treated with at least a corticosteroid and a TPO-RA.

The study consists of the screening period, the primary endpoint assessment period, the follow-up period. The screening period will last for up to 14 days prior to the first dose of ianalumab. All eligible participants will be treated with the same dose of ianalumab and will complete the primary endpoint assessment period. After completion of the primary endpoint assessment period, all participants will continue in safety monitoring and those with a platelet count ≥30 G/L in absence of a new line of ITP therapy and rescue therapy will also continue in efficacy monitoring. The trial includes an option to offer a second course of ianalumab treatment to participants who achieved confirmed response during the initial course of ianalumab and later lost response to explore the benefit of the second course of treatment. The study will end once all participants have completed 24 months of safety follow-up since their last dose of ianalumab (including the optional second course of ianalumab treatment),or discontinued the study earlier.

03

Conditions studied

  • Primary Immune Thrombocytopenia (ITP)

Keywords

  • Primary immune thrombocytopenia (ITP)
  • ianalumab
  • VAY736
  • B-cell depletion
  • B-cell Activating Factor Receptor (BAFF-R) blockade
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Signed obtained prior to participation in the study.
  • Male or female participants aged 18 years and older on the day of signing informed consent.
  • Confirmed diagnosis of primary ITP.

    • Prior treatment with at least a (±IVIG) and a TPO-RA:
    • Prior additional therapies are allowed; the corticosteroid or the TPO-RA do not need to be the last treatment.
    • Prior response to IVIG/anti-D or a corticosteroid ( count ≥50 G/L) that was not maintained.
  • At last ITP treatment, loss of response, insufficient response, no response or intolerance.
  • Platelet count \<30 G/L and assessed as needing treatment (per physician's discretion) at screening. If concomitant ITP medication is clinically indicated, the platelet assessment showing a value \<30 G/L must be performed after at least 14 days on a stable dose of a corticosteroid or/and a TPO-RA (less than 10% variation from current dose) and continue stable thereafter.

Key exclusion criteria:

  • Diagnosis of secondary thrombocytopenia.
  • Platelet or whole blood transfusion, plasmapheresis, or use of any other rescue medications within 14 days before first ianalumab infusion.
  • Participants with the following conditions at screening:

    • Neutrophils \<1000/mm3.
    • Immunoglobulin G (IgG) \<5 g/L
  • Treatment with a B-cell depleting therapy (e.g., rituximab) or anti-B-cell Activating Factor of the TNF Family (BAFF) (e.g., belimumab) within 12 weeks prior to the first administration of ianalumab.
  • drugs other than corticosteroids within 5 times the elimination half-life of the drug or 14 days before first ianalumab infusion, whichever is longer.
  • Prior splenectomy.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Single-arm

    All eligible participants will receive ianalumab at the same dose.

    Biological: Ianalumab

Interventions

  • BiologicalIanalumab

    Intravenous infusion, prepared from concentrate solution

    Also known as: VAY736

06

What researchers measure

Primary outcomes

  1. Confirmed response

    Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of: * Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and * New immune thrombocytopenia (ITP) treatment before reaching a confirmed response.

    Time frame: Between Week 1 Day 1 and Week 25 Day 1

Secondary outcomes

  1. Time to confirmed response

    Time from the first administration of ianalumab to the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response as defined by the primary endpoint.

    Time frame: From Week 1 Day 1 to Week 25 Day 1

  2. Duration of confirmed response

    Time from the first assessment in the first sequence of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events: * platelet count \<30 G/L, * start of any rescue or new ITP treatment, * death (whatever the cause).

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  3. Complete Response rate at each timepoint

    Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  4. Response rate at each timepoint

    Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  5. Stable response at 6 months

    Percentage of participants with at least 75% of platelet counts collected at month 6 (between study days 121 and 183) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment.

    Time frame: At 6 months

  6. Stable response at 1 year

    Percentage of participants with at least 66% of platelet counts collected at year 1 (between study days 296 and 379) equal to or above 50 G/L in the absence of rescue treatment/new ITP treatment.

    Time frame: At 1 year

  7. Bleeding events according to the Modified World Health Organization (WHO) bleeding scale

    Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  8. Percentage of participants with bleeding events according to the Modified World Health Organization (WHO) bleeding scale

    Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  9. Number of participants who received rescue treatment

    Number of participants who required rescue treatment

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  10. Percentage of participants who received rescue treatment

    Percentage of participants who required rescue treatment

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  11. Change from baseline in the frequency of CD19+ B-cell counts

    Post-baseline frequency of CD19+ B-cell counts compared to baseline

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  12. Change from baseline in the absolute number of CD19+ B-cell counts

    Post-baseline absolute number of CD19+ B-cell counts compared to baseline

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  13. Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL

    Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  14. Change from baseline in immunoglobulins

    Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to baseline

    Time frame: From Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  15. Incidence of anti-ianalumab antibodies in serum (ADA assay) over time

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

    Time frame: Up to 20 weeks after last dose of ianalumab

  16. Titer of anti-ianalumab antibodies in serum (ADA assay) over time

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

    Time frame: Up to 20 weeks after last dose of ianalumab

  17. Ianalumab serum concentrations over time

    Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

    Time frame: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

  18. Ianalumab serum PK: AUC concentrations over time

    Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

    Time frame: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

  19. Ianalumab serum PK parameters: Cmax

    Maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

    Time frame: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

  20. Ianalumab serum PK parameters: Tmax

    Time to reach maximum (peak) observed plasma, blood, serum or other body fluid drug concentration

    Time frame: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose)

  21. Confirmed response (CR) in the second course

    Confirmed response is defined as a platelet count of equal or above 50 G/L at two (or more) consecutive assessments at least 7 days apart, in the absence of: * Rescue treatment for ≥4 weeks prior to the assessment of the platelet count, and * New ITP treatment before reaching a confirmed response.

    Time frame: Second course Week 1 Day1 to second course Week 25 Day1

  22. Time to confirmed response in the second course

    two (or more) platelet assessments meeting the criteria of a confirmed response.

    Time frame: Second course Week 1 Day 1 to second course Week 25 Day 1

  23. Duration of confirmed response in the second course

    Time from the first assessment, in the second course of two (or more) platelet assessments meeting the criteria of a confirmed response to loss of response; with loss of response defined as the first of the following events: * platelet count \<30 G/L, * start of any rescue or new ITP treatment, * death (whatever the cause).

    Time frame: Second course Week 1 Day 1 to second course Week 25 Day 1

  24. Response in the second course

    Percentage of participants with a platelet count of at least 50 G/L in the absence of rescue treatment/new ITP treatment.

    Time frame: Second course Week 1 Day 1 to second course Week 25 Day 1

  25. Complete Response in the second course

    Percentage of participants with a platelet count of at least 100 G/L in the absence of rescue treatment/new ITP treatment.

    Time frame: Second course Week 1 Day 1 to second course Week 25 Day 1

  26. Bleeding events in the second course according to the Modified World Health Organization (WHO) bleeding scale

    Number of participants reporting bleeding events for each grade of the World Health Organization (WHO) bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

    Time frame: Second course Week 1 Day 1 to second course Week 25 Day 1

  27. Percentage of participants with bleeding events in the retreatment/second courseaccording to the Modified World Health Organization (WHO) bleeding scale

    Percentage of participants reporting bleeding events for each grade of the WHO bleeding scale at each time point. Severity is graded from 0 to 4, with 0 = no bleeding and 4 = severe hemodynamic instability/central nervous system (CNS) bleeding/fatal.

    Time frame: Second course Week 1 Day 1 to second course Week 25 Day 1

  28. Number of Participants who received rescue treatment after second course

    Number of participants who required rescue treatment

    Time frame: Second course Week 1 Day 1 to second course Week 25 Day 1

  29. Percentage of participants who received rescue treatment after receiving second course

    Percentage of participants who required rescue treatment

    Time frame: Second course Week 1 Day 1 to second course Week 25 Day 1

  30. Titer of anti-ianalumab antibodies in serum (ADA assay) over time for second course

    Anti-drug antibodies (ADA) will be evaluated in samples collected from all participants to assess the immunogenicity of ianalumab

    Time frame: Second course Week 1 Day 1 until 20 weeks after last dose of ianalumab

  31. Change from start of second course in immunoglobulins

    Post-baseline immunoglobulin levels (change in titers of Total Ig, IgG, IgM, IgA) compared to retreatment baseline

    Time frame: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  32. Change from start of second course in the absolute number of CD19+ B-cell counts

    Post-baseline absolute number of CD19+ B-cell counts compared to baseline

    Time frame: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  33. Change from start of second course to end of study in the absolute number of CD19+ B-cell counts

    Post-baseline absolute number of CD19+ B-cell counts compared to baseline

    Time frame: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  34. Time to first occurrence of B-cell recovery defined as ≥80% of baseline ≥50 cells/µL

    Time to B-cell recovery defined as ≥80% of baseline or ≥50 cells/µL

    Time frame: From second course Week 1 Day 1 to end of study (until all participants have completed 24 months of safety follow-up since their last dose of ianalumab or discontinued the study earlier)

  35. Ianalumab serum concentrations over time in the second course

    Ianalumab concentration in serum over time, including end of infusion and concentration at trough.

    Time frame: First dose (pre-dose, 2, 168, 336, 504, 672 hours post-dose); Subsequent doses (pre-dose and 2 hours post-dose); Last dose (pre-dose, 2 336, 672, 1344, 2016, 3360 hours post-dose) in the second course

07

Study locations

24 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Beth Israel Deaconess Med Center
    Boston, Massachusetts 02215, United States
  • Novartis Investigative Site
    CABA, C1181ACH, Argentina
  • Novartis Investigative Site
    Garran, Australian Capital Territory 2605, Australia
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
  • Novartis Investigative Site
    Wuhan, Hubei 430022, China
  • Novartis Investigative Site
    Beijing, 100730, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Toulouse, 31059, France
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Jena, Thuringia 07740, Germany
  • Novartis Investigative Site
    Giessen, 35392, Germany
  • Novartis Investigative Site
    Torino, TO 10126, Italy
  • Novartis Investigative Site
    Johor Bahru, 80100, Malaysia
  • Novartis Investigative Site
    Katowice, 40-519, Poland
  • Novartis Investigative Site
    Seoul, 06591, South Korea
  • Novartis Investigative Site
    Barcelona, Catalonia 08003, Spain
  • Novartis Investigative Site
    Aydin, Efeler 09100, Turkey (Türkiye)
  • Novartis Investigative Site
    Istanbul, Fatih 34098, Turkey (Türkiye)
  • Novartis Investigative Site
    Edirne, Merkez 22030, Turkey (Türkiye)
  • Novartis Investigative Site
    Izmir, 35100, Turkey (Türkiye)
  • Novartis Investigative Site
    Kocaeli, 41380, Turkey (Türkiye)
  • Novartis Investigative Site
    Glasgow, G31 2ER, United Kingdom
  • Novartis Investigative Site
    London, W12 0HS, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

Data sharing details ↗ · www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Feb 2025, 17 months.

Of 66 phase 2 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 41. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 15, 2023
First posted
Jun 2, 2023
StartActual
Aug 16, 2023
Primary completionActual
Feb 5, 2025
CompletionEst.
Mar 19, 2029
Results delay requested
Jan 27, 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05885555
Responsible party
Sponsor
First posted
Jun 2, 2023
Start date
Aug 16, 2023
Primary completion
Feb 5, 2025
Completion
Mar 19, 2029 (estimated)
Last update
Oct 20, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ianalumab

Start the discussion